The assays measure phosphorylated tau 181 and apolipoprotein 4 to rule out whether a patient has Alzheimer's disease.

NEW YORK – With the launch of its first product, a rule-out test for pancreatic cysts that can help risk-stratify patients who may have pancreatic cancer, Purdue University spinout Amplified Sciences ...

The firm said that investors provided better-than-expected backing as the company anticipates growing use of its digital pathology platform in 2025.

The purchase includes the manufacturing process of four ELISA kits, two of which are in vitro diagnostic products for specialty diagnostics and disease monitoring.

The Switzerland-based firm's MosaiQ AiPlex Connective Tissue Diseases (CTDplus) assay is used to aid the diagnosis of autoimmune diseases.

The aggregate repurchase authorization program now totals $200 million, which the firm will fund with cash and cash equivalents.

NEW YORK — ABL Diagnostics said on Wednesday that it has signed an agreement for the distribution of its infectious disease molecular assays in India with Genient Tech Private.

The firm's next-generation sequencing-based test detects single nucleotide variants, insertions, and deletions in 22 genes.

The firm said that it has received approval for a test that combines the Allsheng-developed Auto-Pure 2400 liquid handling platform with Revvity's T-SPOT.TB test.

IBL will develop biomarker panels for use with Grifols' random-access, single-molecule counting platform, and the firms will collaborate on testing workflows.

The firm recently announced agreements with Labcorp and Quest Diagnostics to provide its devices for self-collection of vaginal swab specimens.

Last week, readers were most interested in a story about the overturning by a federal court of the FDA's LDT rule.